# Synthesis, molecular docking studies and biological evaluation of N-(4-oxo-2-(trifluoromethyl)-4H-chromen-7-yl) benzamides as potential antioxidant, and anticancer agents

**Authors:** Sumalatha Jorepalli, Sreedevi Adikay, Radha Rani Chinthaparthi, Chandra Sekhar Reddy Gangireddy, Janardhan Reddy Koduru, Rama Rao Karri

PMC · DOI: 10.1038/s41598-024-59166-5 · Scientific Reports · 2024-04-29

## TL;DR

Researchers synthesized new chromone compounds that show potential as antioxidant and anticancer agents with good results in cell line tests.

## Contribution

A new series of chromone derivatives was synthesized and evaluated for antioxidant and anticancer activities.

## Key findings

- Compound 4h showed strong cytotoxicity against lung and breast cancer cell lines.
- The compounds exhibited significant antioxidant activity in multiple assays.
- Molecular docking suggested strong binding to HERA and Peroxiredoxins proteins.

## Abstract

A series of novel chromone derivatives of (N-(4-oxo-2-(trifluoromethyl)-4H-chromen-6-yl) benzamides) were synthesized by treating 7-amino-2-(trifluoromethyl)-4H-chromen-4-one with K2CO3 and/or NaH, suitable alkyl halides and acetonitrile and/or 1,4-dioxane. The obtained products are in high yields (87 to 96%) with various substituents in short reaction times with no more by-products and confirmed by FT-IR, 1H, and 13C-NMR Spectral data. The in vitro cytotoxic activity was examined against two human cancer cell lines, namely the human lung adenocarcinoma (A-549) and the human breast (MCF-7) cancer cell line. Compound 4h showed promising cytotoxicity against both cell lines with IC50 values of 22.09 and 6.40 ± 0.26 µg/mL respectively, compared to that of the standard drug. We also performed the in vitro antioxidant activity by DPPH radical, hydrogen peroxide, NO scavenging, and total antioxidant capacity (TAC) assay methods, and they showed significant activities. The possible binding interactions of all the synthesized chromone derivatives are also investigated against selective pharmacological targets of human beings, such as HERA protein for cytotoxic activity and Peroxiredoxins (3MNG) for antioxidant activity which showed closer binding free energies than the standard drugs and evidencing the above two types of activities.

## Linked entities

- **Proteins:** ERAL1 (Era like 12S mitochondrial rRNA chaperone 1)
- **Chemicals:** K2CO3 (PubChem CID 11430), NaH (PubChem CID 938), acetonitrile (PubChem CID 6342), 1,4-dioxane (PubChem CID 31275), hydrogen peroxide (PubChem CID 784)
- **Diseases:** lung adenocarcinoma (MONDO:0005061), breast cancer (MONDO:0004989)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** ERAL1 (Era like 12S mitochondrial rRNA chaperone 1) [NCBI Gene 26284] {aka CEGA, ERA, ERA-W, ERAL1A, ERAL1B, H-ERA}
- **Diseases:** breast (MESH:D061325), cytotoxic (MESH:D064420), lung adenocarcinoma (MESH:D000077192), cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** A-549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), MCF-7) cancer — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11058781/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11058781/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC11058781/full.md

---
Source: https://tomesphere.com/paper/PMC11058781